RPID vs. OMIC, HLTH, AXDX, TLIS, PRE, PRPO, BNGO, DTIL, SEER, and GBS
Should you be buying Rapid Micro Biosystems stock or one of its competitors? The main competitors of Rapid Micro Biosystems include Singular Genomics Systems (OMIC), Cue Health (HLTH), Accelerate Diagnostics (AXDX), Talis Biomedical (TLIS), Prenetics Global (PRE), Precipio (PRPO), Bionano Genomics (BNGO), Precision BioSciences (DTIL), Seer (SEER), and GBS (GBS). These companies are all part of the "medical" sector.
Singular Genomics Systems (NASDAQ:OMIC) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.
Singular Genomics Systems received 9 more outperform votes than Rapid Micro Biosystems when rated by MarketBeat users. Likewise, 46.43% of users gave Singular Genomics Systems an outperform vote while only 26.67% of users gave Rapid Micro Biosystems an outperform vote.
Rapid Micro Biosystems has a net margin of -224.73% compared to Rapid Micro Biosystems' net margin of -3,863.90%. Singular Genomics Systems' return on equity of -42.25% beat Rapid Micro Biosystems' return on equity.
Rapid Micro Biosystems has higher revenue and earnings than Singular Genomics Systems. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.
65.8% of Singular Genomics Systems shares are held by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are held by institutional investors. 22.2% of Singular Genomics Systems shares are held by insiders. Comparatively, 30.4% of Rapid Micro Biosystems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Singular Genomics Systems presently has a consensus price target of $0.63, suggesting a potential upside of 64.00%. Given Rapid Micro Biosystems' higher possible upside, equities analysts plainly believe Singular Genomics Systems is more favorable than Rapid Micro Biosystems.
In the previous week, Singular Genomics Systems had 9 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 9 mentions for Singular Genomics Systems and 0 mentions for Rapid Micro Biosystems. Singular Genomics Systems' average media sentiment score of 0.00 beat Rapid Micro Biosystems' score of -0.04 indicating that Rapid Micro Biosystems is being referred to more favorably in the news media.
Singular Genomics Systems has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Rapid Micro Biosystems has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
Summary
Singular Genomics Systems and Rapid Micro Biosystems tied by winning 8 of the 16 factors compared between the two stocks.
Get Rapid Micro Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPID and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rapid Micro Biosystems Competitors List
Related Companies and Tools
